Cystoid and diabetic macular edema treated with nepafenac 0.1%.
Cystoid macular edema (CME), a common complication following cataract surgery, is routinely medically treated with topical nonsteroidal anti-inflammatory drugs (NSAIDs), alone or in combination with steroids. In this paper, we describe 6 patients with CME and 1 patient with diabetic macular edema (DME), all of whom were treated with nepafenac 0.1%, a novel prodrug NSAID. Three (3) patients with acute CME following cataract surgery were treated for 3-4 weeks with nepafenac 0.1%, with or without concomitant steroids. Both retinal thickness and visual acuity improved in all 3 cases. The 3 patients with chronic CME, each of whom had been previously treated with steroids with or without concomitant NSAID therapy, were started on nepafenac 0.1% three times daily. Retinal thickness and visual acuity improved in each case, except for 1 patient with 20/25 pretreatment visual acuity. The mean improvement in visual acuity of all 6 CME patients was 2.5 lines and the mean decrease in retinal thickness was 282.8 microm. The patient with DME also showed improvement in retinal thickness and visual acuity after 6 months of treatment with nepafenac. These clinical data strongly suggest that nepafenac 0.1% is a promising drug for the treatment of posterior segment inflammation, including CME, and warrants further investigation.
Hariprasad
Seenu M
SM
Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL 60637, USA. retina@uchicago.edu
Callanan
David
D
Gainey
Steven
S
He
Yu-Guang
YG
Warren
Keith
K
D000368:Aged; D044482:Benzeneacetamides / Q000627:therapeutic use*; D002387:Cataract Extraction / Q000009:adverse effects; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007910:Lenses, Intraocular / Q000009:adverse effects; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D010648:Phenylacetates / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
D044482:Benzeneacetamides; D010648:Phenylacetates; D013256:Steroids; C414203:nepafenac